Galderma Group AG Surpasses Expectations with Strong First Quarter Performance

Galderma Group AG, a Switzerland-based holding company specializing in dermatological treatments and skin care products, has started the year on a high note, surpassing expectations with a 5.4% increase in sales for the first quarter of 2025. The company’s net sales reached 1.129 billion USD, up 8.3% year-on-year on a constant currency basis, driven primarily by volume and a favorable mix.

Record First Quarter Net Sales

Galderma’s strong performance in the first quarter is a testament to the company’s focus on delivering high-quality products and services to its customers. The company’s net sales benefited from focused execution and favorable phasing, resulting in a significant increase in revenue. This growth is a result of the company’s commitment to innovation and its ability to bring new products to market.

New Product Launches

Galderma has been actively expanding its portfolio of products, with a recent launch of the “Scratch Resistance” campaign for NEMLUVIO, a treatment for eczema itch. This campaign aims to motivate patients to seek treatment for relentless itch, highlighting the physical and emotional burdens of atopic dermatitis. NEMLUVIO is the first and only approved neuroimmune targeted treatment that directly targets IL-31, a key driver of itch, inflammation, and skin barrier dysfunction in patients with atopic dermatitis.

Market Performance

Galderma’s strong first quarter performance has set the tone for the rest of the year. The company’s market capitalization stands at 21.02 billion CHF, with a price-to-earnings ratio of 99.51. The company’s stock price has been steadily increasing, with a close price of 80.6 CHF on April 22, 2025.

Conclusion

Galderma Group AG’s strong first quarter performance is a testament to the company’s commitment to delivering high-quality products and services to its customers. The company’s focus on innovation and its ability to bring new products to market have driven significant growth in revenue. As the company continues to expand its portfolio of products, it is likely to maintain its position as a leader in the dermatological treatments and skin care market.

Key Statistics

  • Net sales: 1.129 billion USD
  • Increase in sales: 5.4% year-on-year
  • Constant currency basis: 8.3% increase
  • Market capitalization: 21.02 billion CHF
  • Price-to-earnings ratio: 99.51
  • Stock price: 80.6 CHF (April 22, 2025)